Chemomab Therapeutics (CMMB) Competitors $0.89 +0.01 (+0.56%) Closing price 03:59 PM EasternExtended Trading$0.87 -0.02 (-2.25%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. MGX, ARTV, ZIVO, IVVD, IRD, RPTX, INMB, IMMX, MNOV, and GANXShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Metagenomi (MGX), Artiva Biotherapeutics (ARTV), ZIVO Bioscience (ZIVO), Invivyd (IVVD), Opus Genetics (IRD), Repare Therapeutics (RPTX), INmune Bio (INMB), Immix Biopharma (IMMX), MediciNova (MNOV), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Its Competitors Metagenomi Artiva Biotherapeutics ZIVO Bioscience Invivyd Opus Genetics Repare Therapeutics INmune Bio Immix Biopharma MediciNova Gain Therapeutics Metagenomi (NASDAQ:MGX) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Is MGX or CMMB more profitable? Chemomab Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -257.99%. Metagenomi's return on equity of -37.84% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-257.99% -37.84% -27.15% Chemomab Therapeutics N/A -94.71%-76.53% Does the media refer more to MGX or CMMB? In the previous week, Metagenomi had 14 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 19 mentions for Metagenomi and 5 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.92 beat Metagenomi's score of 0.32 indicating that Chemomab Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MGX or CMMB? Metagenomi has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Do institutionals and insiders have more ownership in MGX or CMMB? 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, MGX or CMMB? Chemomab Therapeutics has lower revenue, but higher earnings than Metagenomi. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M1.39-$78.06M-$2.36-0.82Chemomab TherapeuticsN/AN/A-$13.94M-$0.59-1.51 Do analysts prefer MGX or CMMB? Metagenomi currently has a consensus target price of $10.00, suggesting a potential upside of 418.13%. Chemomab Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 855.06%. Given Chemomab Therapeutics' higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than Metagenomi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryChemomab Therapeutics beats Metagenomi on 7 of the 13 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.69M$3.11B$5.76B$9.59BDividend YieldN/A2.23%4.41%4.09%P/E Ratio-1.517.3322.4021.92Price / SalesN/A398.09472.14121.31Price / CashN/A43.1937.7358.48Price / Book1.758.129.536.61Net Income-$13.94M-$54.72M$3.26B$265.56M7 Day Performance-4.30%2.62%2.11%1.98%1 Month Performance-20.54%7.63%5.12%1.33%1 Year Performance-27.05%13.11%31.25%21.15% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics3.3467 of 5 stars$0.89+0.6%$8.50+855.1%-27.5%$16.69MN/A-1.5120News CoverageShort Interest ↓Analyst RevisionHigh Trading VolumeMGXMetagenomi2.5418 of 5 stars$1.86-3.3%$10.00+438.8%-44.3%$70.37M$52.29M-0.79236Trending NewsAnalyst ForecastAnalyst RevisionARTVArtiva Biotherapeutics2.8625 of 5 stars$2.87-7.5%$17.00+492.5%-72.5%$70.09M$250K0.0081ZIVOZIVO Bioscience0.2804 of 5 stars$18.04-2.4%N/A+102.4%$68.86M$15.85K-3.7010News CoverageGap UpIVVDInvivyd4.0285 of 5 stars$0.57-2.8%$3.85+581.4%-39.9%$67.78M$25.38M-0.61100Trending NewsShort Interest ↓Analyst RevisionIRDOpus Genetics1.6614 of 5 stars$1.11-3.5%$7.33+560.7%N/A$66.50M$15.42M-0.5814RPTXRepare Therapeutics2.3137 of 5 stars$1.54flat$4.50+192.2%-48.5%$66.16M$53.48M-0.60180INMBINmune Bio2.0666 of 5 stars$2.45-3.4%$18.40+652.6%-65.7%$64.99M$10K-0.9910IMMXImmix Biopharma3.2701 of 5 stars$2.23-3.0%$7.00+213.9%+0.0%$64.29MN/A-2.909MNOVMediciNova2.352 of 5 stars$1.34+1.9%$7.00+424.3%+6.6%$64.25M$1M-5.3410Positive NewsGANXGain Therapeutics2.6411 of 5 stars$1.76-0.6%$7.80+343.2%+34.1%$63.63M$50K-2.8120 Related Companies and Tools Related Companies MGX Competitors ARTV Competitors ZIVO Competitors IVVD Competitors IRD Competitors RPTX Competitors INMB Competitors IMMX Competitors MNOV Competitors GANX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access